Phaseline

Companies › Alixer Nexgen Therapeutics

Alixer Nexgen Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALDP001 Nasal Spray–Phase 2Seasonal Allergic Rhinitis (SAR)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07219849ALDP001 Nasal SprayPhase 2Seasonal Allergic Rhinitis (SAR)ImmunologyApr 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Calixis Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Qifeng Zhang Topadur Pharma Leadingtac Pharmaceutical (Shaoxing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.